NCT02335411View on ClinicalTrials.gov

A Study of Pembrolizumab (MK-3475) in Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-059/KEYNOTE-059)

PHASE2CompletedINTERVENTIONAL
Enrollment

318

Participants

Timeline

Start Date

February 3, 2015

Primary Completion Date

July 23, 2021

Study Completion Date

July 23, 2021

Conditions
Gastric AdenocarcinomaGastroesophageal Junction Adenocarcinoma
Interventions
BIOLOGICAL

pembrolizumab

IV infusion

DRUG

cisplatin

IV infusion

DRUG

5-FU

IV infusion

DRUG

capecitabine

oral tablets

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT02335411 - A Study of Pembrolizumab (MK-3475) in Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-059/KEYNOTE-059) | Biotech Hunter | Biotech Hunter